| The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. | |
| | |
MedLine Citation:
|
PMID: 11037896 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To investigate the relationship between the 4G/5G polymorphism of the type 1 plasminogen activator inhibitor (PAI-1) gene and thrombotic manifestations in patients with antiphospholipid syndrome (APS). METHODS: We studied a total of 247 patients included in the following 4 groups: 70 patients with primary APS, 104 patients with systemic lupus erythematosus (40 with antiphospholipid antibodies [aPL] and clinical [secondary] APS, 13 with aPL but without clinical APS, and 51 with neither detectable aPL nor a history of thrombosis), 14 asymptomatic individuals with aPL, and 59 patients with thrombosis but without known thrombosis risk factors. A control group of 100 healthy individuals was also analyzed. PAI-1 4G/5G polymorphism was determined by polymerase chain reaction and endonuclease digestion. RESULTS: The allele frequency of 4G/5G in controls was 0.47/0.53. There were no differences in allele distribution among patient groups or between patients and controls. However, a higher frequency of the 4G allele was observed in APS patients with versus those without thrombosis (0.57 versus 0.39; P < 0.05) (odds ratio [OR] 2.83, 95% confidence interval [95% CI] 1.18-6.76). This higher frequency of the 4G allele was attributable to the higher frequency in patients with versus those without arterial thrombosis (0.64 versus 0.43; P < 0.01) (OR 5.96, 95% CI 1.67-21.32), while patients with venous thrombosis had an allele distribution similar to that of those without venous thrombosis (0.49 versus 0.50; P not significant). There was a trend toward higher PAI-1 antigen and activity levels in APS patients and controls with the 4G/4G genotype, but this did not reach statistical significance. CONCLUSION: The presence of the 4G allele of the 4G/5G polymorphism of the PAI-1 gene may be an additional risk factor for the development of arterial thrombosis in APS. |
| | |
Authors:
|
D Tàssies; G Espinosa; F J Muñoz-Rodríguez; C Freire; R Cervera; J Monteagudo; S Maragall; G Escolar; M Ingelmo; A Ordinas; J Font; J C Reverter |
Related Documents
:
|
8680786 - Venous thromboembolism in association with prolonged air travel. 1853306 - Impaired fibrinolysis and postoperative thromboembolism in orthopedic patients. 2169216 - Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. 8260336 - Occult malignancy is associated with venous thrombosis unresponsive to adequate anticoa... 920916 - Fasting volume and acidity of stomach contents associated with gastrointestinal symptoms. 3261966 - Development of connective tissue disease in patients presenting with raynaud's phenomen... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Arthritis and rheumatism Volume: 43 ISSN: 0004-3591 ISO Abbreviation: Arthritis Rheum. Publication Date: 2000 Oct |
Date Detail:
|
Created Date: 2000-10-18 Completed Date: 2000-10-31 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0370605 Medline TA: Arthritis Rheum Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 2349-58 Citation Subset: AIM; IM |
Affiliation:
|
Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Barcelona, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antiphospholipid Syndrome / complications*, genetics Arterial Occlusive Diseases / epidemiology, etiology, genetics Cytokines / blood Female Fibrinolysis / genetics Humans Interleukin-6 / blood Male Middle Aged Plasminogen Activator Inhibitor 1 / genetics* Polymorphism, Genetic Risk Factors Tumor Necrosis Factor-alpha / analysis Venous Thrombosis / etiology*, genetics |
| Chemical | |
Reg. No./Substance:
|
0/Cytokines; 0/Interleukin-6; 0/Plasminogen Activator Inhibitor 1; 0/Tumor Necrosis Factor-alpha |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled t...
Next Document: Muscle abnormalities in juvenile dermatomyositis patients: P-31 magnetic resonance spectroscopy stud...